The prevalence of xerostomia, once considered mostly a condition of the elderly or those with disease-related symptoms, has increased to one in four individuals. This increase is attributed to side effects of medications such as weight loss drugs, the use of CPAP machines, and the rising use of marijuana. A new initiative spearheaded by K Pharmaceuticals, manufacturer of Aquoral Protective Oral Spray, aims to address the growing dry mouth crisis and its related systemic implications. The company has introduced what it calls the first ever in-office personalized xerostomia protocol (PXP) for dental professionals.
The protocol was created in partnership with Melissa Turner, BASDH, RDHEP, EFDA, a registered dental hygienist and dental brand strategist.
“Xerostomia has become a silent pandemic that can be detrimental to our patients’ systemic health, often diminishing their quality of life,” Turner says. “Ironically, many individuals suffering from dry mouth remain unaware of their condition. The PXP seeks to heighten awareness among dental and medical providers and patients, enabling us to propel the conversation forward and together stand up for xerostomia relief.”
According to a press release, the PXP tool marks a significant step toward establishing comprehensive global xerostomia guidelines. It is designed for use with every patient at every appointment, offering a straightforward method to identify and educate patients on dry mouth symptoms, outline treatment guidelines, and adapt and re-evaluate therapy based on evolving health needs.
Aquoral, a patented, prescription-strength dry mouth relief spray, has been clinically proven to offer lasting protection of oral tissues, the press release states. Its patented lipid-based formulation creates a protective barrier on the oral mucosa that remains intact after eating or drinking, making it an excellent complement to existing xerostomia therapies.
“Patients in both dental and medical practices have suffered too long without an effective solution,” says Bennett Blakeman, CEO of K Pharmaceuticals. “Many have described Aquoral as a transformative product, which inspired the development of our new PXP. Our mission is to ensure communities no longer have to suffer from this preventable condition or its often detrimental systemic effects.”
Founded in 2022, K Pharmaceuticals is a privately held pharmaceutical company with a mission to make innovative medications more accessible to patients. Aquoral is being brought back to market by K Pharmaceuticals. More information about the product is available at aquoralspray.com/dashboard. The company’s conference schedule is located at aquoralspray.com/programs, and information on continuing education programs for CE credit is located at aquoralspray.com/conferences.
Figures and Images
